Califf Supports Combo Products Pathway At Confirmation Hearing
This article was originally published in The Pink Sheet Daily
FDA's concepts for new pathway could be ready for congressional scrutiny within a year.
You may also be interested in...
Jeffrey Shuren and Janet Woodcock tell Senate committee that agency is more concerned with implementing combination product provisions of the 21st Century Cures Act.
Academic authors say that more than half of FDA medical reviewers leave to either work or consult to industry; experts chime in with mixed reactions to the findings.
Pilot project sets timelines for lead and consulting centers that will feed into more substantial changes in PDUFA VI.